Market news
TypeAll
SortNewest
Assets
CLSD
Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
- XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection...
Aug 30Barchart.com
CLSD
Clearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan Sponsor
NEW YORK, July 15, 2026--Clearside Biomedical, Inc. ("Clearside" or the "Company") today announced that it has completed its financial restructuring and emerged from Chapter 11. All conditions to the effectiveness of the Company’s plan of reorganization (the "Plan"), as confirmed by the United States Bankruptcy Court for the District of Delaware, have been satisfied or waived, and the Plan became effective on the closing date. The Plan was sponsored by Steel Partners, Ltd. ("Steel Partners"), wh
Jul 14Yahoo FinanceCLSD
This is the newest page. Registered accounts read further back.